CN118755703A - 新型透明质酸水解酶突变体和包含其的药物组合物 - Google Patents
新型透明质酸水解酶突变体和包含其的药物组合物 Download PDFInfo
- Publication number
- CN118755703A CN118755703A CN202411133487.0A CN202411133487A CN118755703A CN 118755703 A CN118755703 A CN 118755703A CN 202411133487 A CN202411133487 A CN 202411133487A CN 118755703 A CN118755703 A CN 118755703A
- Authority
- CN
- China
- Prior art keywords
- amino acid
- variant
- fragment
- terminus
- region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
- C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2474—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01035—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Reproductive Health (AREA)
- Plant Pathology (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20180086308 | 2018-07-25 | ||
| KR10-2018-0086308 | 2018-07-25 | ||
| KR10-2019-0029758 | 2019-03-15 | ||
| KR20190029758 | 2019-03-15 | ||
| PCT/KR2019/009215 WO2020022791A1 (ko) | 2018-07-25 | 2019-07-25 | 신규 히알루론산 가수분해 효소 변이체 및 이를 포함하는 약제학적 조성물 |
| CN201980023392.4A CN111971387A (zh) | 2018-07-25 | 2019-07-25 | 新型透明质酸水解酶突变体和包含其的药物组合物 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201980023392.4A Division CN111971387A (zh) | 2018-07-25 | 2019-07-25 | 新型透明质酸水解酶突变体和包含其的药物组合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN118755703A true CN118755703A (zh) | 2024-10-11 |
Family
ID=69182377
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202411133487.0A Pending CN118755703A (zh) | 2018-07-25 | 2019-07-25 | 新型透明质酸水解酶突变体和包含其的药物组合物 |
| CN202411127100.0A Pending CN118792283A (zh) | 2018-07-25 | 2019-07-25 | 新型透明质酸水解酶突变体和包含其的药物组合物 |
| CN202411131157.8A Pending CN118853631A (zh) | 2018-07-25 | 2019-07-25 | 新型透明质酸水解酶突变体和包含其的药物组合物 |
| CN202411131388.9A Pending CN118773171A (zh) | 2018-07-25 | 2019-07-25 | 新型透明质酸水解酶突变体和包含其的药物组合物 |
| CN201980023392.4A Pending CN111971387A (zh) | 2018-07-25 | 2019-07-25 | 新型透明质酸水解酶突变体和包含其的药物组合物 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202411127100.0A Pending CN118792283A (zh) | 2018-07-25 | 2019-07-25 | 新型透明质酸水解酶突变体和包含其的药物组合物 |
| CN202411131157.8A Pending CN118853631A (zh) | 2018-07-25 | 2019-07-25 | 新型透明质酸水解酶突变体和包含其的药物组合物 |
| CN202411131388.9A Pending CN118773171A (zh) | 2018-07-25 | 2019-07-25 | 新型透明质酸水解酶突变体和包含其的药物组合物 |
| CN201980023392.4A Pending CN111971387A (zh) | 2018-07-25 | 2019-07-25 | 新型透明质酸水解酶突变体和包含其的药物组合物 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US12371683B2 (enExample) |
| EP (1) | EP3636752A4 (enExample) |
| JP (3) | JP7204729B2 (enExample) |
| KR (3) | KR20210023798A (enExample) |
| CN (5) | CN118755703A (enExample) |
| AU (2) | AU2019311658B2 (enExample) |
| BR (1) | BR112020019041A2 (enExample) |
| CA (1) | CA3093885A1 (enExample) |
| MX (1) | MX2020009824A (enExample) |
| RU (1) | RU2766680C1 (enExample) |
| WO (1) | WO2020022791A1 (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG177008A1 (en) | 2003-03-05 | 2012-01-30 | Halozyme Inc | Soluble hyaluronidase glycoprotein (shasegp), process for preparing the same, uses and pharmaceutical compositions comprising thereof |
| PT3130347T (pt) | 2011-12-30 | 2019-12-10 | Halozyme Inc | Variantes de polipéptidos de ph20, suas formulações e utilizações |
| CN118755703A (zh) | 2018-07-25 | 2024-10-11 | 阿特根公司 | 新型透明质酸水解酶突变体和包含其的药物组合物 |
| BR112021008873A8 (pt) | 2018-11-07 | 2023-04-11 | Merck Sharp & Dohme | Formulação |
| KR20230037691A (ko) * | 2019-03-25 | 2023-03-16 | (주)알테오젠 | 인간 히알루로니다제 ph20의 변이체와 약물을 포함하는 피하투여용 약학 조성물 |
| KR102801434B1 (ko) * | 2020-01-23 | 2025-04-30 | (주)알테오젠 | 안정성이 향상된 신규 히알루론산 가수분해 효소 변이체 및 이를 포함하는 약제학적 조성물 |
| MX2023000760A (es) | 2020-07-17 | 2023-02-13 | Geron Corp | Composiciones subcutaneas del inhibidor de la telomerasa y metodos para su uso. |
| CN120738156A (zh) * | 2020-08-07 | 2025-10-03 | 阿特根公司 | 制备重组玻尿酸酶的方法 |
| KR20230074516A (ko) * | 2020-09-24 | 2023-05-30 | 머크 샤프 앤드 돔 엘엘씨 | 프로그램화된 사멸 수용체 1 (pd-1) 항체 및 히알루로니다제 변이체 및 그의 단편의 안정한 제제 및 그의 사용 방법 |
| WO2022146948A1 (en) | 2020-12-28 | 2022-07-07 | Bristol-Myers Squibb Company | Subcutaneous administration of pd1/pd-l1 antibodies |
| AU2021411486A1 (en) | 2020-12-28 | 2023-06-29 | Bristol-Myers Squibb Company | Antibody compositions and methods of use thereof |
| TW202305009A (zh) | 2021-04-08 | 2023-02-01 | 美商默沙東有限責任公司 | 以皮下投予抗pd1抗體治療癌症之方法 |
| CN115671267A (zh) | 2021-07-23 | 2023-02-03 | 上海宝济药业有限公司 | 一种皮下抗生素药物组合物 |
| WO2023012515A2 (en) | 2021-08-02 | 2023-02-09 | argenx BV | Subcutaneous unit dosage forms |
| KR20240055077A (ko) | 2021-09-14 | 2024-04-26 | 다케다 야쿠힌 고교 가부시키가이샤 | 히알루로니데이스를 이용한 농축된 항체 제형의 촉진된 전달 |
| KR20230064559A (ko) * | 2021-10-29 | 2023-05-10 | (주)알테오젠 | 인간 히알루로니다제 ph20과 약물을 포함하는 약학 조성물 |
| EP4469586A1 (en) | 2022-03-01 | 2024-12-04 | Exuma Biotech Corp. | Viral particles with membrane-bound hyaluronidase |
| CN114573715A (zh) * | 2022-03-14 | 2022-06-03 | 江苏雅酶医药科技有限公司 | 一种重组长效人透明质酸酶及其生产方法和应用 |
| KR20230150203A (ko) | 2022-04-20 | 2023-10-30 | 주식회사 알토스바이오로직스 | 오크렐리주맙(Ocrelizumab)을 포함하는 약학적 조성물과 그의 용도 |
| US20250332252A1 (en) | 2022-06-02 | 2025-10-30 | Bristol-Myers Squibb Company | Antibody compositions and methods of use thereof |
| KR102774438B1 (ko) * | 2022-06-08 | 2025-02-27 | (주)한국비엠아이 | 히알루로니다제 폴리펩티드 및 이의 용도 |
| WO2023249408A1 (ko) * | 2022-06-22 | 2023-12-28 | (주)알테오젠 | N-말단 및/또는 c-말단이 절단된 가용성 ph20 폴리펩티드 및 이의 용도 |
| CN119421949A (zh) * | 2022-06-29 | 2025-02-11 | 奥德斯根株式会社 | 中性pH中显示活性的透明质酸酶Hyal1变体 |
| KR102621518B1 (ko) * | 2022-06-29 | 2024-01-10 | 주식회사 오디스젠 | 중성 pH에서 활성을 나타내는 히알루로니다제 Hyal1변이체 |
| EP4562048A1 (en) * | 2022-07-28 | 2025-06-04 | Merck Sharp & Dohme LLC | Pharmaceutical compositions of programmed death receptor 1 (pd-1) antibodies and ph20 variants or fragments thereof |
| WO2024025989A1 (en) * | 2022-07-28 | 2024-02-01 | Merck Sharp & Dohme Llc | Pharmaceutical compositions of programmed death receptor 1 (pd-1) antibodies and rhuph20 or variants or fragments thereof |
| KR20240038901A (ko) * | 2022-09-16 | 2024-03-26 | (주)피앤피바이오팜 | 신규한 히알루로니다제 ph-20 변이체 및 그 용도 |
| CN120936341A (zh) | 2022-12-22 | 2025-11-11 | 海洋酶公司 | 用于高体积施用的透明质酸酶制剂 |
| KR20250162568A (ko) * | 2023-03-23 | 2025-11-18 | (주)알테오젠 | 신규 히알루론산 가수분해 효소 변이체 및 이를 포함하는 약제학적 조성물 |
| KR20250086876A (ko) * | 2023-12-06 | 2025-06-16 | (주)한국비엠아이 | 히알루로니다제 폴리펩티드와 약물을 포함하는 피하투여용 조성물 |
| KR102896967B1 (ko) * | 2023-12-21 | 2025-12-09 | 주식회사 오디스젠 | 개선된 특성을 갖는 히알루로니다제 Hyal2 변이체 |
| WO2025136032A1 (ko) * | 2023-12-21 | 2025-06-26 | 주식회사 오디스젠 | 개선된 특성을 갖는 히알루로니다제 hyal2 변이체 |
| KR102875495B1 (ko) * | 2023-12-28 | 2025-10-27 | 주식회사 오디스젠 | 히알루로니다제 Hyal1 변이체 |
| CN119776311B (zh) * | 2024-12-13 | 2025-12-19 | 江南大学 | 一种透明质酸合酶突变体及其应用 |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5721348A (en) | 1990-12-14 | 1998-02-24 | University Of Connecticut | DNA encoding PH-20 proteins |
| US5958750A (en) | 1996-07-03 | 1999-09-28 | Inctye Pharmaceuticals, Inc. | Human hyaluronidase |
| US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| US20090123367A1 (en) | 2003-03-05 | 2009-05-14 | Delfmems | Soluble Glycosaminoglycanases and Methods of Preparing and Using Soluble Glycosaminoglycanases |
| SG177008A1 (en) | 2003-03-05 | 2012-01-30 | Halozyme Inc | Soluble hyaluronidase glycoprotein (shasegp), process for preparing the same, uses and pharmaceutical compositions comprising thereof |
| US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
| CA2628959A1 (en) | 2005-11-10 | 2007-06-07 | Receptor Biologix, Inc. | Methods for production of receptor and ligand isoforms |
| US8288142B2 (en) | 2007-06-19 | 2012-10-16 | Uvarkina Tamara P | Hyaluronidase and method of use thereof |
| ITMI20072225A1 (it) | 2007-11-23 | 2009-05-24 | Luso Farmaco Inst | "composizioni farmaceutiche a base di antagonisti della bradichinina ed acido ialuronico e loro uso" |
| WO2009111066A1 (en) | 2008-03-06 | 2009-09-11 | Halozyme, Inc. | Large-scale production of soluble hyaluronidase |
| TWI489994B (zh) | 2008-03-17 | 2015-07-01 | Baxter Healthcare Sa | 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法 |
| US20100003238A1 (en) | 2008-04-14 | 2010-01-07 | Frost Gregory I | Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions |
| ES2573462T3 (es) | 2008-12-09 | 2016-06-08 | Halozyme, Inc. | Polipéptidos de PH20 soluble extendida y usos de los mismos |
| NZ593641A (en) | 2008-12-09 | 2013-01-25 | Halozyme Inc | Extended soluble ph20 polypeptides and uses thereof |
| ES2385251B1 (es) | 2009-05-06 | 2013-05-06 | Fundació Privada Institut D'investigació Biomèdica De Bellvitge | Adenovirus oncolíticos para el tratamiento del cáncer. |
| WO2010138918A1 (en) | 2009-05-29 | 2010-12-02 | Pacira Pharmaceuticals, Inc. | Hyaluronidase as an adjuvant for increasing the injection volume and dispersion of large diameter synthetic membrane vesicles containing a therapeutic agent |
| US9345661B2 (en) | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
| AR078161A1 (es) | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento. |
| CN102655853B (zh) | 2009-09-17 | 2015-07-29 | 巴克斯特卫生保健有限公司 | 透明质酸酶和免疫球蛋白的稳定的复合制剂及其使用方法 |
| RU2563346C2 (ru) | 2011-03-31 | 2015-09-20 | Мерк Шарп И Доум Корп. | Стабильные составы антител против рецептора программируемой смерти pd-1 человека и относящиеся к ним способы лечения |
| CA2839511C (en) | 2011-06-17 | 2018-07-31 | Halozyme, Inc. | Stable formulations of a hyaluronan-degrading enzyme |
| PT3130347T (pt) | 2011-12-30 | 2019-12-10 | Halozyme Inc | Variantes de polipéptidos de ph20, suas formulações e utilizações |
| CN103173474B (zh) | 2013-03-27 | 2014-08-27 | 广州白云山拜迪生物医药有限公司 | 一种用于cho细胞表达可溶性重组人透明质酸酶ph20的基因序列 |
| JP6357363B2 (ja) | 2013-06-26 | 2018-07-11 | 株式会社半導体エネルギー研究所 | 記憶装置 |
| TW201534726A (zh) * | 2013-07-03 | 2015-09-16 | Halozyme Inc | 熱穩定ｐｈ２０玻尿酸酶變異體及其用途 |
| KR20160085269A (ko) | 2013-11-13 | 2016-07-15 | 틸로츠 파마 아게 | 다중-미립자 약물전달 시스템 |
| JP6841656B2 (ja) | 2013-12-17 | 2021-03-10 | ジェネンテック， インコーポレイテッド | Ｐｄ−１軸結合アンタゴニスト及びタキサンを使用する癌の治療方法 |
| US20170218382A1 (en) | 2014-07-31 | 2017-08-03 | National University Corporation Kobe University | Secretion Signal Peptide, And Protein Secretory Production And Cell Surface Display Using Said Secretion Signal Peptide |
| DK3186281T3 (da) * | 2014-08-28 | 2019-06-11 | Halozyme Inc | Kombinationsterapi med et hyaluronan-nedbrydende enzym og en immun-checkpoint-inhibitor |
| JP6625627B2 (ja) | 2014-10-14 | 2019-12-25 | ハロザイム インコーポレイテッド | アデノシンデアミナーゼ−２（ａｄａ２）、その変異体の組成物およびそれを使用する方法 |
| CN104745553B (zh) | 2015-03-27 | 2017-11-28 | 杭州北斗生物技术有限公司 | 重组人透明质酸酶及其制备方法和采用聚乙二醇共价修饰的化合物和方法 |
| CA2896038C (en) | 2015-07-03 | 2022-08-09 | Glycobiosciences Inc. | Polymer matrix compositions comprising a high concentration of bio-fermented sodium hyaluronate and uses thereof |
| US9995753B2 (en) | 2015-09-25 | 2018-06-12 | Merck Sharp & Dohme Corp. | Anti-pembrolizumab antibodies |
| RS61651B1 (sr) | 2015-11-03 | 2021-04-29 | Janssen Biotech Inc | Potkožne formulacije anti-cd38 antitela i njihova upotreba |
| AR107483A1 (es) | 2016-01-29 | 2018-05-02 | Hanmi Pharm Ind Co Ltd | Conjugado de enzimas terapéuticas |
| CN105567606B (zh) | 2016-03-02 | 2019-03-19 | 青岛海洋生物医药研究院股份有限公司 | 一种球形节杆菌及其产生的透明质酸酶 |
| CN110167601A (zh) | 2016-11-30 | 2019-08-23 | 纪念斯隆凯特琳癌症中心 | 抑制剂-功能化超微小纳米粒子和其方法 |
| ES2969041T3 (es) | 2017-03-02 | 2024-05-16 | Genentech Inc | Tratamiento adyuvante del cáncer de mama positivo para HER2 |
| US20210101980A1 (en) | 2017-03-31 | 2021-04-08 | Bristol-Myers Squibb Company | Methods of treating tumor |
| JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
| CN118356488A (zh) | 2017-05-30 | 2024-07-19 | 百时美施贵宝公司 | 包含抗lag-3抗体或抗lag-3抗体和抗pd-1或抗pd-l1抗体的组合物 |
| US20190351031A1 (en) | 2018-05-16 | 2019-11-21 | Halozyme, Inc. | Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20 |
| CN118755703A (zh) | 2018-07-25 | 2024-10-11 | 阿特根公司 | 新型透明质酸水解酶突变体和包含其的药物组合物 |
| WO2020172621A1 (en) | 2019-02-22 | 2020-08-27 | Memorial Sloan Kettering Cancer Center | Cd33 antibodies and methods of using the same to treat cancer |
| KR20230037691A (ko) | 2019-03-25 | 2023-03-16 | (주)알테오젠 | 인간 히알루로니다제 ph20의 변이체와 약물을 포함하는 피하투여용 약학 조성물 |
| JP2020197994A (ja) | 2019-06-04 | 2020-12-10 | 東芝テック株式会社 | 情報処理装置及びその制御プログラム |
| KR102801434B1 (ko) | 2020-01-23 | 2025-04-30 | (주)알테오젠 | 안정성이 향상된 신규 히알루론산 가수분해 효소 변이체 및 이를 포함하는 약제학적 조성물 |
| CN120738156A (zh) | 2020-08-07 | 2025-10-03 | 阿特根公司 | 制备重组玻尿酸酶的方法 |
| KR20230074516A (ko) | 2020-09-24 | 2023-05-30 | 머크 샤프 앤드 돔 엘엘씨 | 프로그램화된 사멸 수용체 1 (pd-1) 항체 및 히알루로니다제 변이체 및 그의 단편의 안정한 제제 및 그의 사용 방법 |
| KR20230064559A (ko) | 2021-10-29 | 2023-05-10 | (주)알테오젠 | 인간 히알루로니다제 ph20과 약물을 포함하는 약학 조성물 |
-
2019
- 2019-07-25 CN CN202411133487.0A patent/CN118755703A/zh active Pending
- 2019-07-25 RU RU2020130922A patent/RU2766680C1/ru active
- 2019-07-25 WO PCT/KR2019/009215 patent/WO2020022791A1/ko not_active Ceased
- 2019-07-25 BR BR112020019041-1A patent/BR112020019041A2/pt unknown
- 2019-07-25 AU AU2019311658A patent/AU2019311658B2/en active Active
- 2019-07-25 CN CN202411127100.0A patent/CN118792283A/zh active Pending
- 2019-07-25 US US16/628,258 patent/US12371683B2/en active Active
- 2019-07-25 CN CN202411131157.8A patent/CN118853631A/zh active Pending
- 2019-07-25 CA CA3093885A patent/CA3093885A1/en active Pending
- 2019-07-25 KR KR1020207024813A patent/KR20210023798A/ko active Pending
- 2019-07-25 CN CN202411131388.9A patent/CN118773171A/zh active Pending
- 2019-07-25 KR KR1020207002955A patent/KR102151388B1/ko active Active
- 2019-07-25 JP JP2020500863A patent/JP7204729B2/ja active Active
- 2019-07-25 MX MX2020009824A patent/MX2020009824A/es unknown
- 2019-07-25 KR KR1020257002900A patent/KR20250021616A/ko active Pending
- 2019-07-25 CN CN201980023392.4A patent/CN111971387A/zh active Pending
- 2019-07-25 EP EP19827585.1A patent/EP3636752A4/en active Pending
-
2022
- 2022-12-28 JP JP2022211105A patent/JP2023052142A/ja active Pending
-
2023
- 2023-01-20 AU AU2023200324A patent/AU2023200324B9/en active Active
-
2024
- 2024-09-17 JP JP2024159834A patent/JP2025004002A/ja active Pending
-
2025
- 2025-06-06 US US19/231,008 patent/US20250368976A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3093885A1 (en) | 2020-01-30 |
| AU2019311658A8 (en) | 2021-03-25 |
| CN118853631A (zh) | 2024-10-29 |
| JP2023052142A (ja) | 2023-04-11 |
| JP2021507676A (ja) | 2021-02-25 |
| CN111971387A (zh) | 2020-11-20 |
| CN118773171A (zh) | 2024-10-15 |
| AU2019311658B2 (en) | 2022-10-20 |
| US20210155913A1 (en) | 2021-05-27 |
| WO2020022791A1 (ko) | 2020-01-30 |
| US20250368976A1 (en) | 2025-12-04 |
| AU2023200324A1 (en) | 2023-03-02 |
| KR20210023798A (ko) | 2021-03-04 |
| RU2766680C1 (ru) | 2022-03-15 |
| US12371683B2 (en) | 2025-07-29 |
| CN118792283A (zh) | 2024-10-18 |
| AU2019311658A1 (en) | 2021-02-11 |
| AU2023200324B2 (en) | 2025-09-04 |
| EP3636752A4 (en) | 2021-04-28 |
| KR20200017538A (ko) | 2020-02-18 |
| BR112020019041A2 (pt) | 2021-02-09 |
| JP2025004002A (ja) | 2025-01-14 |
| MX2020009824A (es) | 2021-01-15 |
| KR102151388B1 (ko) | 2020-09-04 |
| AU2023200324B9 (en) | 2025-12-04 |
| EP3636752A1 (en) | 2020-04-15 |
| JP7204729B2 (ja) | 2023-01-16 |
| KR20250021616A (ko) | 2025-02-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2023200324B2 (en) | Novel hyaluoronic acid-hydrolyzing enzyme variant and pharmaceutical composition containing same | |
| KR102801434B1 (ko) | 안정성이 향상된 신규 히알루론산 가수분해 효소 변이체 및 이를 포함하는 약제학적 조성물 | |
| JP2001526183A (ja) | ヒアルロニダーゼアイソザイムの精製およびミクロシークエンシング | |
| KR20240110541A (ko) | N-말단 및/또는 c-말단이 절단된 가용성 ph20 폴리펩티드 및 이의 용도 | |
| KR20250162568A (ko) | 신규 히알루론산 가수분해 효소 변이체 및 이를 포함하는 약제학적 조성물 | |
| RU2811464C2 (ru) | Новые варианты гиалуронидазы с улучшенной стабильностью и содержащая их фармацевтическая композиция |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40115820 Country of ref document: HK |